Criterium, Inc.

ACTIVE

358 Broadway Ste 201, Saratoga Springs, New York, United Stateswww.criteriuminc.comPrivate101–250 employeesEstablished: 1991-01-01

Clinical Trials

4 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1991

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

53.9%

Phase 2

46.1%

Trial Status Distribution

Active, not recruiting

30.8%

Completed

15.4%

Recruiting

7.7%

Terminated

38.5%

Withdrawn

7.7%

Clinical Trials

Trials sponsored by this organization (13)

A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

Phase 2

Recruiting

interventional

Oct 2025120 participants

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Phase 2

Active, not recruiting

interventional

Jan 202417 participants

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1

Active, not recruiting

interventional

Aug 202240 participants

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC

Phase 1

Terminated

interventional

May 20222 participants

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1

Terminated

interventional

Apr 20225 participants

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Phase 2

Active, not recruiting

interventional

Feb 202170 participants

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Phase 2

Active, not recruiting

interventional

Dec 201927 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations